News and Media

19 Aug

Robotic Prostate Cancer Surgery On Trial

The first randomised controlled trial to directly compare robotic surgery with open surgery for patients with localised prostate cancer finds that robotic and open surgery achieve similar results in terms of key quality of life indicators at 3 months. The study, published in The Lancet, is the first stage of a 2 year trial and

Read More
19 Aug

Double Blow For Lung Cancer And Emphysema Offers Hope To Patients

Lung cancer and emphysema could be diagnosed earlier and targeted with an existing drug, vastly improving patient outcomes, researchers at Hudson Institute of Medical Research have discovered. A team led by Professor Brendan Jenkins discovered that the drug, sgp130Fc, has the ability to halt the progression of lung cancer and emphysema. Combined these lung diseases

Read More
19 Aug

New Cancer Nanomedicine Reduces Pancreatic Tumour Growth

Prof Tom Davis, Director of the ARC Centre of Excellence in Convergent Bio-Nano Science & Technology at Monash University and his collaborators at UNSW have developed a highly promising technology to deliver gene-silencing drugs to treat pancreatic cancer – the most chemo-resistant and deadly cancer in Australia. When tested in mice, the new nanomedicine resulted in

Read More
19 Aug

Early Detection of Leukaemia Patients’ Resistance To Therapy

Adelaide researchers have made a world-first breakthrough in the early detection of patients’ resistance to a common treatment for chronic myeloid leukaemia, offering some hope that the patients’ treatment could be changed sooner to improve their chances of survival. The researchers – based in the Cancer Theme at the South Australian Health & Medical Research

Read More
19 Aug

Monash Part of World-First Clinical Trial for Lymphoma Patients

A novel therapy for aggressive lymphoma is being tested in a world-first clinical trial at the Monash Health Translation Precinct (MHTP). In early 2015, researchers at Monash University and Peter MacCallum Cancer Centre showed the novel anti-lymphoma therapy is remarkably effective against one of the most aggressive B-cell lymphomas in animal models. Mr George Potter

Read More
19 Aug

First Patient Overnight Stay at MHTP Clinical Trials Centre

The Clinical Trials Centre at the Monash Health Translation Precinct (MHTP) welcomed its first overnight patient earlier this month. Mr Rudy Van Ekeren is the second aggressive B-cell lymphoma patient in Australia—and only the third in the world—to receive a novel epigenetic therapy as part of an anti-lymphoma clinical trial.  The study is being led

Read More
19 Aug

Study Reveals Cholesterol Link In Aggressive Cancers

University of Queensland research has revealed how fats – including cholesterol – could increase the progression of aggressive cancers. UQ Diamantina Institute study leader Associate Professor Michelle Hill said the findings offered potential new treatment strategies and targets. “Our previous research showed a high cholesterol diet increased the spread of prostate cancer tumours to lymph

Read More
Page 8 of 10« First...678910